Literature DB >> 18549891

Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia.

Anathea C Powell1, Constantine A Stratakis, Nicholas J Patronas, Seth M Steinberg, Dalia Batista, H Richard Alexander, James F Pingpank, Meg Keil, David L Bartlett, Steven K Libutti.   

Abstract

BACKGROUND: We reviewed our experience with micronodular adrenal hyperplasia (MAH), its pigmented variant primary pigmented nodular adrenocortical disease (PPNAD), and the association with Carney's complex (CNC) to better characterize these disorders.
METHODS: This retrospective study analyzes clinical data and operative reports of 34 patients identified with MAH and/or PPNAD who underwent resection between 1969 and 2006 at the Clinical Research Center, an inpatient research hospital at the National Institutes of Health. Symptoms and anthropometric and biochemical data were used to evaluate effect of resection.
RESULTS: Fifteen patients (44%) presented as adults and 19 (56%) as children. Twenty-five patients (74%) presented with noncyclic Cushing syndrome and 9 patients (26%) presented with cyclic Cushing syndrome. Thirty-one patients underwent bilateral resection; this was curative biochemically in 30 patients. Fourteen operations were performed laparoscopically (41%), and 20 were performed as open resections (59%). There was 1 postoperative complication in the laparoscopic group (7%) and 6 complications in the open group (30%; P = .20). Follow-up was available for 25 patients (74%). Statistically significant improvements in anthropometrics were observed for both adults and children. The most frequent manifestation of CNC requiring additional operation was cardiac myxoma, which was associated strongly with an atypical (cyclic) presentation of Cushing syndrome (P = .009).
CONCLUSION: Cushing syndrome due to MAH and PPNAD may be cured by bilateral adrenal resection. All patients should be screened for manifestations of CNC at the time of adrenal diagnosis with particular attention to cardiac disease.

Entities:  

Mesh:

Year:  2008        PMID: 18549891      PMCID: PMC2601697          DOI: 10.1016/j.surg.2008.03.022

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  21 in total

Review 1.  Cushing's syndrome in children and adolescents: current diagnostic and therapeutic strategies.

Authors:  M A Magiakou; G P Chrousos
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 2.  The medical management of Cushing's syndrome.

Authors:  Damian Morris; Ashley Grossman
Journal:  Ann N Y Acad Sci       Date:  2002-09       Impact factor: 5.691

Review 3.  Diagnosis and complications of Cushing's syndrome: a consensus statement.

Authors:  G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

4.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

5.  Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity?

Authors:  Daniel F Gunther; Isabelle Bourdeau; Ludmila Matyakhina; David Cassarino; David E Kleiner; Kurt Griffin; Nickolas Courkoutsakis; Mones Abu-Asab; Maria Tsokos; Meg Keil; J Aidan Carney; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

6.  Primary pigmented nodular adrenocortical disease: diagnosis and management.

Authors:  C S Grant; J A Carney; P C Carpenter; J A van Heerden
Journal:  Surgery       Date:  1986-12       Impact factor: 3.982

7.  Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor.

Authors:  Isabelle Bourdeau; André Lacroix; Walter Schürch; Philippe Caron; Tony Antakly; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

8.  Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity.

Authors:  Jerome Bertherat; Lionel Groussin; Fabiano Sandrini; Ludmila Matyakhina; Thalia Bei; Sotirios Stergiopoulos; Theocharis Papageorgiou; Isabelle Bourdeau; Lawrence S Kirschner; Caroline Vincent-Dejean; Karine Perlemoine; Christine Gicquel; Xavier Bertagna; Constantine A Stratakis
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Diagnostic tests for children who are referred for the investigation of Cushing syndrome.

Authors:  Dalia L Batista; Jehan Riar; Meg Keil; Constantine A Stratakis
Journal:  Pediatrics       Date:  2007-08-13       Impact factor: 7.124

10.  Cushing syndrome due to primary pigmented nodular adrenocortical disease: findings at CT and MR imaging.

Authors:  J L Doppman; W D Travis; L Nieman; D L Miller; G P Chrousos; M T Gomez; G B Cutler; D L Loriaux; J A Norton
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

View more
  14 in total

1.  Cushing Syndrome in Carney Complex: Clinical, Pathologic, and Molecular Genetic Findings in the 17 Affected Mayo Clinic Patients.

Authors:  Kathleen M Lowe; William F Young; Charalampos Lyssikatos; Constantine A Stratakis; J Aidan Carney
Journal:  Am J Surg Pathol       Date:  2017-02       Impact factor: 6.394

Review 2.  Diagnosis and Clinical Genetics of Cushing Syndrome in Pediatrics.

Authors:  Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2016-06       Impact factor: 4.741

Review 3.  Phosphodiesterases and adrenal Cushing in mice and humans.

Authors:  E Szarek; C A Stratakis
Journal:  Horm Metab Res       Date:  2014-09-18       Impact factor: 2.936

Review 4.  Cushing syndrome in pediatrics.

Authors:  Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2012-09-27       Impact factor: 4.741

5.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

6.  Use of 3-Dimensional Volumetric Modeling of Adrenal Gland Size in Patients with Primary Pigmented Nodular Adrenocortical Disease.

Authors:  P P Chrysostomou; M B Lodish; E B Turkbey; G Z Papadakis; C A Stratakis
Journal:  Horm Metab Res       Date:  2016-04-11       Impact factor: 2.936

7.  Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors.

Authors:  Hui-Pin Hsiao; Lawrence S Kirschner; Isabelle Bourdeau; Margaret F Keil; Sosipatros A Boikos; Somya Verma; Audrey J Robinson-White; Maria Nesterova; André Lacroix; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2009-06-09       Impact factor: 5.958

8.  Differentially regulated protein kinase A (PKA) activity in adipose tissue and liver is associated with resistance to diet-induced obesity and glucose intolerance in mice that lack PKA regulatory subunit type IIα.

Authors:  Edra London; Maria Nesterova; Ninet Sinaii; Eva Szarek; Tatyana Chanturiya; Spyridon A Mastroyannis; Oksana Gavrilova; Constantine A Stratakis
Journal:  Endocrinology       Date:  2014-06-10       Impact factor: 4.736

Review 9.  Quality of life and other outcomes in children treated for Cushing syndrome.

Authors:  Margaret F Keil
Journal:  J Clin Endocrinol Metab       Date:  2013-05-02       Impact factor: 5.958

10.  Differences in adiposity in Cushing syndrome caused by PRKAR1A mutations: clues for the role of cyclic AMP signaling in obesity and diagnostic implications.

Authors:  Edra London; Anya Rothenbuhler; Maya Lodish; Evgenia Gourgari; Meg Keil; Charalampos Lyssikatos; Maria de la Luz Sierra; Nicolas Patronas; Maria Nesterova; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2013-11-18       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.